Explore

Reuters Reuters
Curium deepens radiopharma heft with up to $8 billion deal for Lantheus

Curium deepens radiopharma heft with up to $8 billion deal for Lantheus

By Kamal Choudhury and Kunal Das Aug 3 (Reuters) - Radiopharmaceutical company Curium has agreed to buy peer Lantheus Holdings in a deal worth up to $8 billion, as the private equity-backed firm looks to expand its footprint in the fast-growing sector.
Trendline Trendline
KKR to Acquire Integer Holdings in $5.7 Billion Deal, Enhancing Medical Device Innovation

KKR to Acquire Integer Holdings in $5.7 Billion Deal, Enhancing Medical Device Innovation

KKR to Acquire Integer Holdings in $5.7 Billion Deal, Enhancing Medical Device Innovation
Trendline Trendline
AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger

AstraZeneca and Bristol Myers Squibb in Talks for $400 Billion Merger
Reuters Reuters
AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says

AstraZeneca held talks with Bristol Myers Squibb on $400 billion megadeal, source says

By Sabrina Valle and Michael Erman Aug 2 (Reuters) - AstraZeneca Plc and Bristol Myers Squibb held preliminary discussions about a possible combination that would create one of the world's biggest pharmaceutical companies with a combined value of nearly $400 billion, according to a person familiar
Trendline Trendline
Curium and Lantheus Announce Merger to Expand Radiopharmaceutical Reach

Curium and Lantheus Announce Merger to Expand Radiopharmaceutical Reach

Curium and Lantheus Announce Merger to Expand Radiopharmaceutical Reach
Trendline Trendline
AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns

AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns

AstraZeneca Explores Potential Merger with Bristol Myers Squibb Amid Patent Concerns
Trendline Trendline
AstraZeneca and Bristol-Myers Squibb Merger Talks Could Create $400 Billion Pharmaceutical Giant

AstraZeneca and Bristol-Myers Squibb Merger Talks Could Create $400 Billion Pharmaceutical Giant

AstraZeneca and Bristol-Myers Squibb Merger Talks Could Create $400 Billion Pharmaceutical Giant
Reuters Reuters
Exclusive-Mexico's largest meat exporter SuKarne explores sale, sources say

Exclusive-Mexico's largest meat exporter SuKarne explores sale, sources say

NEW YORK, Aug 3 (Reuters) - The owner of SuKarne, Mexico's largest meat exporter, is exploring a sale that could value the company at over $2 billion, according to people familiar with the matter.
Reuters Reuters
AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

AstraZeneca holds talks with Bristol Myers Squibb on $400 billion megadeal, FT reports

Aug 2 (Reuters) - UK drugmaker AstraZeneca has been exploring a deal to combine with U.S. rival Bristol Myers Squibb, the Financial Times reported on Sunday, citing people familiar with the matter.
Trendline Trendline
Nathan Kirsh's Wealth Surges as Restaurant Depot Sale Nears Completion

Nathan Kirsh's Wealth Surges as Restaurant Depot Sale Nears Completion

Nathan Kirsh's Wealth Surges as Restaurant Depot Sale Nears Completion
Trendline Trendline
Paramount CEO Prepares for Antitrust Battle Over Warner Bros. Deal

Paramount CEO Prepares for Antitrust Battle Over Warner Bros. Deal

Paramount CEO Prepares for Antitrust Battle Over Warner Bros. Deal
Trendline Trendline
Circle K's Parent Company Alimentation Couche-Tard to Acquire Żabka Group in $8.7 Billion Deal

Circle K's Parent Company Alimentation Couche-Tard to Acquire Żabka Group in $8.7 Billion Deal

Circle K's Parent Company Alimentation Couche-Tard to Acquire Żabka Group in $8.7 Billion Deal